Literature DB >> 28125278

Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.

Valérie Amsellem1, Shariq Abid1, Lucie Poupel1, Aurélien Parpaleix1, Mathieu Rodero1, Guillaume Gary-Bobo1, Mehdi Latiri1, Jean-Luc Dubois-Rande1, Larissa Lipskaia1, Christophe Combadiere1, Serge Adnot1.   

Abstract

Monocytes/macrophages are major effectors of lung inflammation associated with various forms of pulmonary hypertension (PH). Interactions between the CCL2/CCR2 and CX3CL1/CX3CR1 chemokine systems that guide phagocyte infiltration are incompletely understood. Our objective was to explore the individual and combined actions of CCL2/CCR2 and CX3CL1/CX3CR1 in hypoxia-induced PH in mice; particularly their roles in monocyte trafficking, macrophage polarization, and pulmonary vascular remodeling. The development of hypoxia-induced PH was associated with marked increases in lung levels of CX3CR1, CCR2, and their respective ligands, CX3CL1 and CCL2. Flow cytometry revealed that both inflammatory Ly6Chi and resident Ly6Clo monocyte subsets exhibited sustained increases in blood and a transient peak in lung tissue, and that lung perivascular and alveolar macrophage counts showed sustained elevations. CX3CR1-/- mice were protected against hypoxic PH compared with wild-type mice, whereas CCL2-/- mice and double CX3CR1-/-/CCL2-/- mice exhibited similar PH severity, as did wild-type mice. The protective effects of CX3CR1 deficiency occurred concomitantly with increases in lung monocyte and macrophage counts and with a change from M2 to M1 macrophage polarization that markedly diminished the ability of conditioned media to induce pulmonary artery smooth muscle cell (PA-SMC) proliferation, which was partly dependent on CX3CL1 secretion. Results in mice given the CX3CR1 inhibitor F1 were similar to those in CX3CR1-/- mice. In conclusion, CX3CR1 deficiency protects against hypoxia-induced PH by modulating monocyte recruitment, macrophage polarization, and PA-SMC cell proliferation. Targeting CX3CR1 may hold promise for treating PH.

Entities:  

Keywords:  CX3CL1/CX3CR1 and CCL2/CCR2; chemokines; macrophages; monocytes; pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28125278     DOI: 10.1165/rcmb.2016-0201OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  37 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Involvement of Microglial Cells in Hypoxia-induced Pulmonary Hypertension.

Authors:  Aline C Oliveira; Ravindra K Sharma; Victor Aquino; Gilberto Lobaton; Andrew J Bryant; Jeffrey K Harrison; Elaine M Richards; Mohan K Raizada
Journal:  Am J Respir Cell Mol Biol       Date:  2018-08       Impact factor: 6.914

3.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 4.  Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?

Authors:  Kenia Pedrosa Nunes; Amanda Almeida de Oliveira; Francesca Elisabeth Mowry; Vinicia Campana Biancardi
Journal:  Br J Pharmacol       Date:  2018-08-09       Impact factor: 8.739

5.  Nonclassical Monocytes Sense Hypoxia, Regulate Pulmonary Vascular Remodeling, and Promote Pulmonary Hypertension.

Authors:  Yen-Rei A Yu; Yuryi Malakhau; Chen-Hsin A Yu; Stefan-Laural J Phelan; R Ian Cumming; Matthew J Kan; Lan Mao; Sudarshan Rajagopal; Claude A Piantadosi; Michael D Gunn
Journal:  J Immunol       Date:  2020-01-29       Impact factor: 5.422

6.  Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats.

Authors:  James R Klinger; Mandy Pereira; Michael Del Tatto; Alexander S Brodsky; Keith Q Wu; Mark S Dooner; Theodore Borgovan; Sicheng Wen; Laura R Goldberg; Jason M Aliotta; Corey E Ventetuolo; Peter J Quesenberry; Olin D Liang
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

Review 7.  Pulmonary hypertension: Pathophysiology beyond the lung.

Authors:  Aline C Oliveira; Elaine M Richards; Mohan K Raizada
Journal:  Pharmacol Res       Date:  2019-11-13       Impact factor: 7.658

8.  Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Authors:  Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 9.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

10.  Inflammatory Macrophage Expansion in Pulmonary Hypertension Depends upon Mobilization of Blood-Borne Monocytes.

Authors:  Jonathan Florentin; Emilie Coppin; Sathish Babu Vasamsetti; Jingsi Zhao; Yi-Yin Tai; Ying Tang; Yingze Zhang; Annie Watson; John Sembrat; Mauricio Rojas; Sara O Vargas; Stephen Y Chan; Partha Dutta
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.